ENLIGHTEN-1, the Phase 3 trial of eloralintide in obesity without diabetes, opens
Phase IIIP1Primary public evidenceTrial registry record
NCT07321886 lists a start date of 6 February 2026 for a Phase 3 placebo-controlled trial of once-weekly eloralintide in adults with obesity or overweight without type 2 diabetes. The registry lists 1,980 planned participants, 158 locations, a primary endpoint of percent change in body weight at week 64, and primary completion in March 2028.
1,980
Planned participants, as recorded in the registry
Week 64
Time point of the primary endpoint, percent change in body weight
March 2028
Primary completion date listed in the registry
Background and context
Who can take part
Adults need a BMI of at least 30, or at least 27 with a weight-related condition such as high blood pressure, dyslipidemia, obstructive sleep apnea or heart disease. People with type 1 or type 2 diabetes are excluded.
After week 64
The main phase lasts about 75 weeks. Participants with prediabetes continue into a two-year extension that tracks time to onset of type 2 diabetes.
What the record does not say
No results are posted. Secondary measures such as waist circumference, triglycerides and quality-of-life scales are plans, not findings.
Trial record: ClinicalTrials.gov NCT07321886, read on 2026-10-15. Registered plans can change.
P1Primary public evidenceTrial registry record.An official trial registration. A registration shows that a study exists; it does not show that the compound works.
